| pubmed-article:7853573 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7853573 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:7853573 | lifeskim:mentions | umls-concept:C0543467 | lld:lifeskim |
| pubmed-article:7853573 | lifeskim:mentions | umls-concept:C2608055 | lld:lifeskim |
| pubmed-article:7853573 | pubmed:issue | 3 Pt 2 | lld:pubmed |
| pubmed-article:7853573 | pubmed:dateCreated | 1995-3-10 | lld:pubmed |
| pubmed-article:7853573 | pubmed:abstractText | The von Hippel-Lindau syndrome is the most well known cause of familial renal cancer. Because affected individuals with renal lesions can have complex, multisystem manifestations of von Hippel-Lindau disease, our renal management strategy has included parenchymal sparing surgery whenever possible. From May 1988 to January 1993, 20 patients with hereditary renal cell carcinoma (19 with von Hippel-Lindau disease and 1 with hereditary papillary renal cancer) underwent renal exploration with the intent of performing parenchymal sparing surgery. A total of 7 nephrectomies and 27 parenchymal sparing procedures was performed. Additional procedures performed included 2 bilateral adrenalectomies for pheochromocytomas, 1 resection of a renal vein thrombus and 1 resection of a pancreatic islet cell tumor. Renal atrophy occurred in 3 of 27 kidneys (11%) treated by parenchymal sparing surgery. In 8 kidneys of 7 patients new solid lesions developed and in 14 kidneys of 12 patients no new solid lesions developed during a mean followup of 26 months (range 6 to 60 months). The use of parenchymal sparing surgery in patients with familial forms of kidney cancer is based on a desire to maintain renal function as long as possible while reducing the risk of metastases. The potential advantages and disadvantages of more ablative surgical treatment requiring subsequent dialysis or transplantation in patients with existing or potential central nervous system, eye, pancreas and/or adrenal tumors must be weighed against the possibility of renal cancer metastases or recurrence when deciding on the use of parenchymal sparing surgery. | lld:pubmed |
| pubmed-article:7853573 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7853573 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7853573 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7853573 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7853573 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:7853573 | pubmed:issn | 0022-5347 | lld:pubmed |
| pubmed-article:7853573 | pubmed:author | pubmed-author:WeissGG | lld:pubmed |
| pubmed-article:7853573 | pubmed:author | pubmed-author:LinehanW MWM | lld:pubmed |
| pubmed-article:7853573 | pubmed:author | pubmed-author:LongJJ | lld:pubmed |
| pubmed-article:7853573 | pubmed:author | pubmed-author:ReiterRR | lld:pubmed |
| pubmed-article:7853573 | pubmed:author | pubmed-author:AlexanderR... | lld:pubmed |
| pubmed-article:7853573 | pubmed:author | pubmed-author:ChoykeP LPL | lld:pubmed |
| pubmed-article:7853573 | pubmed:author | pubmed-author:ManolatosCC | lld:pubmed |
| pubmed-article:7853573 | pubmed:author | pubmed-author:WaltherM MMM | lld:pubmed |
| pubmed-article:7853573 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7853573 | pubmed:volume | 153 | lld:pubmed |
| pubmed-article:7853573 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7853573 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7853573 | pubmed:pagination | 913-6 | lld:pubmed |
| pubmed-article:7853573 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:7853573 | pubmed:meshHeading | pubmed-meshheading:7853573-... | lld:pubmed |
| pubmed-article:7853573 | pubmed:meshHeading | pubmed-meshheading:7853573-... | lld:pubmed |
| pubmed-article:7853573 | pubmed:meshHeading | pubmed-meshheading:7853573-... | lld:pubmed |
| pubmed-article:7853573 | pubmed:meshHeading | pubmed-meshheading:7853573-... | lld:pubmed |
| pubmed-article:7853573 | pubmed:meshHeading | pubmed-meshheading:7853573-... | lld:pubmed |
| pubmed-article:7853573 | pubmed:meshHeading | pubmed-meshheading:7853573-... | lld:pubmed |
| pubmed-article:7853573 | pubmed:meshHeading | pubmed-meshheading:7853573-... | lld:pubmed |
| pubmed-article:7853573 | pubmed:meshHeading | pubmed-meshheading:7853573-... | lld:pubmed |
| pubmed-article:7853573 | pubmed:meshHeading | pubmed-meshheading:7853573-... | lld:pubmed |
| pubmed-article:7853573 | pubmed:meshHeading | pubmed-meshheading:7853573-... | lld:pubmed |
| pubmed-article:7853573 | pubmed:meshHeading | pubmed-meshheading:7853573-... | lld:pubmed |
| pubmed-article:7853573 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7853573 | pubmed:articleTitle | Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. | lld:pubmed |
| pubmed-article:7853573 | pubmed:affiliation | Urologic Oncology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. | lld:pubmed |
| pubmed-article:7853573 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7853573 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7853573 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7853573 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7853573 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7853573 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7853573 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7853573 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7853573 | lld:pubmed |
